- Home
- IMNN vs TLPH Comparison
IMNN vs TLPH Comparison
Compare IMNN & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- TLPH
- Stock Information
- Founded
- IMNN 1982
- TLPH 2005
- Country
- IMNN United States
- TLPH United States
- Employees
- IMNN N/A
- TLPH N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- TLPH Health Care
- Exchange
- IMNN Nasdaq
- TLPH Nasdaq
- Market Cap
- IMNN 14.3M
- TLPH 13.4M
- IPO Year
- IMNN 1985
- TLPH 2011
- Fundamental
- Price
- IMNN $0.75
- TLPH $0.80
- Analyst Decision
- IMNN Strong Buy
- TLPH Strong Buy
- Analyst Count
- IMNN 2
- TLPH 2
- Target Price
- IMNN $20.50
- TLPH $4.50
- AVG Volume (30 Days)
- IMNN 199.0K
- TLPH 130.8K
- Earning Date
- IMNN 11-07-2024
- TLPH 11-13-2024
- Dividend Yield
- IMNN N/A
- TLPH N/A
- EPS Growth
- IMNN N/A
- TLPH N/A
- EPS
- IMNN N/A
- TLPH N/A
- Revenue
- IMNN N/A
- TLPH $398,000.00
- Revenue This Year
- IMNN N/A
- TLPH N/A
- Revenue Next Year
- IMNN N/A
- TLPH N/A
- P/E Ratio
- IMNN N/A
- TLPH N/A
- Revenue Growth
- IMNN N/A
- TLPH 57.31
- 52 Week Low
- IMNN $0.48
- TLPH $0.46
- 52 Week High
- IMNN $3.65
- TLPH $1.61
- Technical
- Relative Strength Index (RSI)
- IMNN 27.97
- TLPH 37.37
- Support Level
- IMNN $0.71
- TLPH $0.86
- Resistance Level
- IMNN $0.84
- TLPH $0.93
- Average True Range (ATR)
- IMNN 0.07
- TLPH 0.07
- MACD
- IMNN -0.02
- TLPH -0.01
- Stochastic Oscillator
- IMNN 11.00
- TLPH 0.00
About IMNN Imunon Inc.
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.